CCM
MRVI icon

Coldstream Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Coldstream Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,298
Closed -$70.6K – 1249
2025
Q2 		$70.6K Buy
29,298
+10,796
+58% +$22.7K ﹤0.01% 1095
2025
Q1 		$40.9K Buy
+18,502
New +$73.1K ﹤0.01% 1806

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Coldstream Capital Management's MRVI Position: Q3 2025 in Review

Coldstream Capital Management sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 29,298 shares — an estimated $70.6K sold.

Coldstream Capital Management first reported a position in MRVI in Q1 2025 and held it in 2 quarters. The position peaked at $70.6K in Q2 2025. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • Coldstream Capital Management reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 29,298 Maravai LifeSciences shares in Q3 2025, an estimated $70.6K.
  • Coldstream Capital Management first reported a position in Maravai LifeSciences in Q1 2025 and held it in 2 quarters.
  • Coldstream Capital Management's Maravai LifeSciences position peaked at $70.6K in Q2 2025.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Coldstream Capital Management's 13F filing for Q3 2025, filed 19 Nov 2025.